Irbesartan Paired in Therapy with Dapagliflozin on Glucose and Lipid In-dexes and Renal Function in Patients with Diabetic Nephropathy
Objective To investigate irbesartan paired in therapy with daglipin on glucose and lipid indexes and renal function in patients with diabetic nephropathy(DN).Methods A total of 300 cases DN patients admitted to the Second Hospital of Longyan City in from February 2021 to February 2024 were selected randomly as the research objects and divided into control group and observation group according to different medication regimens,with 150 cases in each group.The control group received irbesartan monotherapy,and the observation group was treated with dapagliflozin based on the medication conditions of the control group.The efficacy,glycolipid index,renal function and medication safety of the two groups were compared.Results The total effective rate of treatment in the observation group was 92.67%(139/150),which was higher than 84.00%(126/150)in the control group,and the difference was statistically significant(χ2=5.466,P=0.019).The levels of fasting blood glucose,2 h postprandial blood glucose,triglyceride and total cholesterol in the observation group were lower than those in the control group,and the differences were statisti-cally significant(all P<0.05).The serum creatinine value,24 h urinary protein quantitative value and urinary protein excretion rate in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of total adverse drug reactions between patients in two groups(P>0.05).Conclusion Irbesartan combined with dapagliflozin has significant effect in the treat-ment of DN,which can significantly improve the glucose and lipid indexes and renal function of patients,and ensure the safety of medication.
IrbesartanDapagliflozin Diabetic nephropathyGlycolipid indexRenal function
NETL
NSTL
万方数据
